The 2026 Healthtech Messaging Index
Cleerly
cleerlyhealth.com·scored September 1, 2026
15/38
Weak
The signal is faint. Most of this page is about Cleerly, not the buyer, and AI has little it can repeat. There's a lot of room to move.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for AI-powered coronary artery disease analysis software for CCTA interpretation, it named:
Buyer we put in the prompt: Cardiologist or radiologist at a hospital, health system, or cardiology practice making clinical decisions about CAD diagnosis and CCTA reporting. Both the buyer and the category were inferred from Cleerly’s homepage alone. The model had no web access.
Cleerly was on the list.
AI named them for their own category. That's the signal every homepage is supposed to send.
AI named you when asked who it recommends for "AI-powered coronary artery disease analysis software for CCTA interpretation", and described you accurately: "Cleerly is an AI-based platform focused on quantifying coronary plaque composition and burden from CCTA imaging to support non-invasive CAD diagnosis and risk stratification.". Your positioning is landing with the machines.
Overall assessment
Cleerly's biggest strength is its clinical evidence ... the CREDENCE and PACIFIC trial data with 868 FFR reference measurements and head-to-head comparisons to FFRCT and SPECT give it rare, concrete proof in a category full of vague AI claims. The biggest gap is narrative: the page never articulates a buyer problem, names no enemy or status quo, shows zero social proof from named customers, and opens with a feature list instead of a story ... leaving a massive persuasion gap that evidence alone cannot close.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
02Rebellion / Movement
“No named enemy, named status quo, or named industry pattern the company is pushing against anywhere on the page.”
There is no rebellion framing ... no critique of traditional stress testing, catheterization over-reliance, or any named incumbent approach that Cleerly is displacing.
All 19 signals, scored 0 to 2.
Total 15/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“Get AI-powered insights on: Stenosis, Plaque volume, Plaque phenotype, Ischemia likelihood, Serial CCTA scans”
A medical professional could infer this is cardiac imaging AI, but a stranger can't instantly grasp who it's for, what specific problem it solves, or what point of view it takes ... the hero is a feature list, not a clear narrative.
- 0
02Rebellion / Movementweakest
“No named enemy, named status quo, or named industry pattern the company is pushing against anywhere on the page.”
There is no rebellion framing ... no critique of traditional stress testing, catheterization over-reliance, or any named incumbent approach that Cleerly is displacing.
- 1
03Owned Language & Category
“Cleerly ISCHEMIA" and "PREVIEW" appear as product names, and "quantifies atherosclerosis" is used specifically.”
Cleerly ISCHEMIA and PREVIEW hint at owned product language, but no broader category name or overarching framework is coined or claimed that an AI would quote back as Cleerly's alone.
- 1
04ICP Clarity
“I am a... Medical Provider / Patient”
The page segments visitors but gives no specificity on role (cardiologist vs. radiologist?), practice size, or clinical setting, so ICP clarity is weak.
- 0
05Problem Leadership
“No buyer problem stated before the solution; page opens with "Get AI-powered insights on: Stenosis, Plaque volume...”
The page leads immediately with product features and capabilities, never articulating the buyer's pain or diagnostic challenge before pitching the solution.
- 1
06Solution Clarity
“Cleerly is a comprehensive, AI-driven platform that quantifies and assesses coronary artery disease (CAD) to deliver clinically actionable insights”
A visitor can form a rough sentence about what Cleerly does, but 'comprehensive AI-driven platform delivering clinically actionable insights' is generic enough that it doesn't stick as a memorable one-liner.
- 0
07Cost of Inaction
“No mention of cost of inaction, missed diagnoses, downstream testing costs, or patient risk from status quo anywhere on the page.”
The page never names the stakes of not acting ... no lost time, no missed CAD events, no unnecessary procedures ... leaving the urgency case completely unmade.
- 1
08Promised Land
“potentially reducing the need for additional testing and enhancing diagnostic confidence”
There is a vague after-state implied (fewer tests, more confidence) but it is hedged with 'potentially' and never painted as a vivid, specific promised land the buyer will inhabit.
Trust Signal
4 signals
- 2
09Proof & Evidence
“Cleerly ISCHEMIA demonstrated higher diagnostic accuracy and area under the curve compared to FFRCT and stress testing, as referenced to 868 invasive measurements”
The CREDENCE and PACIFIC trial data provide concrete comparative numbers and named reference standards, which is specific, clinical proof rather than adjective-driven claims.
- 0
10Social Proof
“No customer logos, named testimonials, case studies with patient or provider names, or video stories anywhere on the page.”
Social proof is entirely absent ... no named customers, no provider testimonials, no health system logos, nothing to show who already uses and trusts Cleerly.
- 1
11Authority & Credibility
“Awards shown: "Digital Health Best in Class," "AI Breakthrough Award Best Overall," "Fierce 15 Award," "Digital Health 150”
Industry awards are displayed but no founder credentials, original frameworks, research authorship, or institutional affiliations are cited to demonstrate authority beyond logo badges.
- 0
12Alternatives Acknowledged
“No mention of alternative approaches, competing tools, or the 'do nothing' option anywhere on the page.”
The page never acknowledges that buyers could choose FFRCT software, traditional stress testing, or no change ... competitors are referenced only in trial data, not as acknowledged alternatives.
AI Signal
6 signals
- 1
13Customer Focus
“Collaborating with Cleerly for cardiac care assessments may empower better treatment decisions and improve diagnostic testing and patient outcomes”
The page mixes company-capability language with occasional customer benefit references, but Cleerly's own features and platform are the clear protagonist, not the provider's or patient's transformation story.
- 1
14AI-Parmesan Index
“Cleerly is a comprehensive, AI-driven platform" and "Get AI-powered insights”
AI is named but the page does provide some mechanistic substance (machine learning variables, plaque quantification, CCTA analysis) so it's not pure AI-Parmesan, but the hero copy uses AI as a label rather than explaining the mechanism.
- 1
15LLM Quotability
“Cleerly ISCHEMIA was the only non-invasive ischemia test that was prognostic of future MACE events, FFRCT and SPECT were not.”
This sentence from the PACIFIC trial is close to LLM-quotable and declarative, but the surrounding page lacks a crisp, standalone positioning sentence an LLM could lift to recommend Cleerly to a buyer.
- 0
16Copyright Freshness
“No visible dates on any content, no copyright year visible in the scraped content, no dated blog posts or case studies.”
There are zero recency signals in the scraped content ... no publication dates, no copyright year, nothing for AI engines to use as a freshness indicator.
- 1
17Entity Distinctiveness
“Cleerly ISCHEMIA demonstrated higher diagnostic accuracy...compared to FFRCT and stress testing, as referenced to 868 invasive measurements by FFR”
The clinical trial data and named product lines (Cleerly ISCHEMIA, PREVIEW) provide some distinctiveness, but the core positioning language ('AI-driven platform,' 'clinically actionable insights') is interchangeable with multiple cardiac AI competitors.
- 2
18AI Recommendation Check
“AI described you as: "Cleerly is an AI-based platform focused on quantifying coronary plaque composition and burden from CCTA imaging to support non-invasive CAD diagnosis and risk stratification.”
AI named you when asked who it recommends for "AI-powered coronary artery disease analysis software for CCTA interpretation", and described you accurately: "Cleerly is an AI-based platform focused on quantifying coronary plaque composition and burden from CCTA imaging to support non-invasive CAD diagnosis and risk stratification.". Your positioning is landing with the machines.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“Request a Demo" appears as primary CTA; "See the Cleerly Difference" and "Explore Our Technology" also present as secondary links.”
There is a primary CTA (Request a Demo) and soft secondary links, but no visible numbered process or workflow path connecting steps to the CTA, so the conversion architecture is incomplete.
Keep the lead
AI already names Cleerly. The next edition decides if it still does.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Cleerly the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.